Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Treasury Shares: 2016-2024

Historic Treasury Shares for Collegium Pharmaceutical (COLL) over the last 4 years, with Dec 2024 value amounting to $197.5 million.

  • Collegium Pharmaceutical's Treasury Shares rose 29.08% to $222.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.5 million, marking a year-over-year increase of 29.08%. This contributed to the annual value of $197.5 million for FY2024, which is 43.76% up from last year.
  • According to the latest figures from FY2024, Collegium Pharmaceutical's Treasury Shares is $197.5 million, which was up 43.76% from $137.4 million recorded in FY2023.
  • Collegium Pharmaceutical's 5-year Treasury Shares high stood at $8.2 million for FY2024, and its period low was $2.2 million during FY2021.
  • Its 3-year average for Treasury Shares is $5.9 million, with a median of $6.3 million in 2023.
  • Data for Collegium Pharmaceutical's Treasury Shares shows a peak YoY skyrocketed of 121.85% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Collegium Pharmaceutical's Treasury Shares stood at $42.9 million in 2021, then surged by 44.48% to $61.9 million in 2022, then skyrocketed by 121.85% to $137.4 million in 2023, then spiked by 43.76% to $197.5 million in 2024.